The oral kinase inhibitor pacritinib (PAC) yielded greater spleen volume reduction than best available therapy — including ruxolitinib — for myelofibrosis patients. If PAC passes the safety test, the impact could be huge.
The Protocol T study has led to lasting changes in how we manage diabetic macular edema at Cole Eye Institute.
How botulinum toxin plays an important role in the conservative management of TMJ and many other noncosmetic head and neck conditions.
Novel treatments for BPH significantly lower the risk of complications from surgical prostate removal that may cause problems with erections, ejaculations and incontinence.
AML studies report effectiveness of vadastuximab, an anti-CD33 drug conjugate, in various regimens including combined with azacitidine and as part of maintenance regimens. Investigators predict changes to standard treatment of AML in the near future.
For large brain metastases, could two medium-high doses of Gamma Knife therapy a month apart be better than the standard single dose? A pioneer of this novel approach explains why it’s a game changer.
A new low-dose drug-coated balloon shows superiority over standard balloon angioplasty in one of the most complex patient groups studied to date, paving the way for FDA submission.
After only one year of operation, Cleveland Clinic Abu Dhabi has earned the Joint Commission International’s (JCI) prestigious Gold Seal of Approval® for hospital accreditation with a compliance score of 99 percent. The award is a global symbol of quality that reflects the organization’s commitment to providing safe and effective patient care.
Cleveland Clinic researchers are first to test eltrombopag during 7+3 induction chemotherapy in AML. Interim data suggest eltrombopag can accelerate platelet recovery and potentially reduce the need for platelet transfusions.
Cleveland Clinic researchers identified risk factors predictive of bleeding events among hospitalized cancer patients. Findings may help optimize appropriateness of thromboprophylaxis.